Andrew Carr

5.8k total citations · 1 hit paper
64 papers, 3.8k citations indexed

About

Andrew Carr is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Carr has authored 64 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Infectious Diseases, 29 papers in Virology and 23 papers in Epidemiology. Recurrent topics in Andrew Carr's work include HIV/AIDS drug development and treatment (36 papers), HIV/AIDS Research and Interventions (31 papers) and HIV Research and Treatment (29 papers). Andrew Carr is often cited by papers focused on HIV/AIDS drug development and treatment (36 papers), HIV/AIDS Research and Interventions (31 papers) and HIV Research and Treatment (29 papers). Andrew Carr collaborates with scholars based in Australia, United States and United Kingdom. Andrew Carr's co-authors include David A. Cooper, Matthew Law, Katherine Samaras, Samantha Burton, Donald J. Chisholm, Judith Freund, Janaki Amin, Vincent Mooser, Michiel A. van Agtmael and Winnie Tong and has published in prestigious journals such as The Lancet, PLoS ONE and Nature Reviews Drug Discovery.

In The Last Decade

Andrew Carr

61 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1998 1.9k citations Andrew Carr, Matthew Law et al. AIDS profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Carr Australia	26	2.5k	2.3k	1.9k	749	349	64	3.8k
E. McKinnon Australia	25	1.3k 0.5×	1.2k 0.5×	1.1k 0.6×	717 1.0×	263 0.8×	90	2.9k
Anne Simon France	28	1.8k 0.7×	1.0k 0.4×	1.7k 0.9×	859 1.1×	211 0.6×	99	3.0k
Nicholas I. Paton United Kingdom	18	1.4k 0.6×	1.7k 0.7×	1.4k 0.7×	493 0.7×	184 0.5×	39	2.7k
Isabelle Poizot‐Martin France	31	1.6k 0.7×	805 0.3×	1.1k 0.5×	1.2k 1.6×	197 0.6×	154	3.2k
Federica Carli Italy	21	1.1k 0.4×	1.6k 0.7×	597 0.3×	644 0.9×	114 0.3×	42	2.2k
Jordi Puig Spain	27	1.1k 0.4×	667 0.3×	910 0.5×	429 0.6×	167 0.5×	102	2.3k
Fraser Drummond Australia	11	1.2k 0.5×	1.5k 0.7×	1.1k 0.6×	508 0.7×	188 0.5×	18	2.2k
Jean‐Paul Viard France	30	1.8k 0.7×	556 0.2×	1.8k 0.9×	713 1.0×	101 0.3×	98	3.4k
Núria Pérez‐Álvarez Spain	26	1.0k 0.4×	803 0.3×	853 0.4×	404 0.5×	87 0.2×	80	1.9k
Ana Milinkovic Spain	25	1.4k 0.5×	890 0.4×	771 0.4×	818 1.1×	61 0.2×	70	2.3k

Countries citing papers authored by Andrew Carr

Since Specialization

Citations

This map shows the geographic impact of Andrew Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Carr more than expected).

Fields of papers citing papers by Andrew Carr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Carr. The network helps show where Andrew Carr may publish in the future.

Co-authorship network of co-authors of Andrew Carr

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Carr. A scholar is included among the top collaborators of Andrew Carr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Carr. Andrew Carr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ezard, Nadine, Krista J. Siefried, Robert Ali, et al.. (2024). Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial. Addiction. 120(7). 1345–1359. 2 indexed citations

Hruby, George, Jennifer M. Roberts, Andrew Carr, et al.. (2023). Anal cancer: a 20‐year retrospective study from Australia. ANZ Journal of Surgery. 93(11). 2697–2705. 1 indexed citations

Chan, Curtis, Douglas Fraser, Stefanie Vaccher, et al.. (2021). Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial. Sexual Health. 18(6). 453–459. 15 indexed citations

Ezard, Nadine, Adrian Dunlop, Raimondo Bruno, et al.. (2021). Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open. 11(5). e044696–e044696. 14 indexed citations

Carr, Andrew, et al.. (2020). Additive and Synergistic Cardiovascular Disease Risk Factors and HIV Disease Markers' Effects on White Matter Microstructure in Virally Suppressed HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 84(5). 543–551. 8 indexed citations

Carr, Andrew, Birgit Grund, Anchalee Avihingsanon, et al.. (2019). The rate of bone loss slows after 1–2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. HIV Medicine. 21(1). 64–70. 12 indexed citations

Carr, Andrew, et al.. (2018). Success and failure of initial antiretroviral therapy in adults. AIDS. 33(3). 443–453. 11 indexed citations

Zablotska, Iryna, Stefanie Vaccher, Mark Bloch, et al.. (2018). High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE. AIDS and Behavior. 23(7). 1780–1789. 28 indexed citations

McAllister, John, Janet M Towns, Anna McNulty, et al.. (2017). Dolutegravir with tenofovir disoproxil fumarate–emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS. 31(9). 1291–1295. 16 indexed citations

10.

Siefried, Krista J., Limin Mao, Stephen J. Kerr, et al.. (2017). Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression. PLoS ONE. 12(4). e0174613–e0174613. 28 indexed citations

11.

Roberts, Jennifer M., Fengyi Jin, Julia K. Thurloe, et al.. (2015). High reproducibility of histological diagnosis of human papillomavirus-related intraepithelial lesions of the anal canal. Pathology. 47(4). 308–313. 13 indexed citations

12.

Cysique, Lucette A., Nadene Dermody, Andrew Carr, Bruce J. Brew, & Maree Teesson. (2015). The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults. Journal of NeuroVirology. 22(1). 56–65. 22 indexed citations

13.

Tong, Winnie, Suzanne M. Garland, Alan P. Meagher, et al.. (2014). Human Papillomavirus 16–Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions. The Journal of Infectious Diseases. 211(3). 405–415. 24 indexed citations

14.

Jansson, James, David P. Wilson, Andrew Carr, Kathy Petoumenos, & Mark Boyd. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS. 27(8). 1245–1251. 11 indexed citations

15.

Carr, Andrew, Jennifer Hoy, & Anton Pozniak. (2012). The Ethics of Switch/Simplify in Antiretroviral Trials: Non-Inferior or Just Inferior?. PLoS Medicine. 9(7). e1001240–e1001240. 16 indexed citations

16.

Agtmael, Michiel A. van, et al.. (2010). Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(1). 78–81. 100 indexed citations

17.

Calmy, Alexandra, Kathy Petoumenos, Charlotte Lewden, et al.. (2007). Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Medicine. 8(3). 171–180. 12 indexed citations

18.

Winston, Alan, Mark Bloch, Andrew Carr, et al.. (2005). Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 56(2). 380–387. 42 indexed citations

19.

Carr, Andrew. (2003). Toxicity of antiretroviral therapy and implications for drug development. Nature Reviews Drug Discovery. 2(8). 624–634. 153 indexed citations

20.

Imrie, Allison, Andrew Carr, Chris Duncombe, et al.. (1996). Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Does Not Adversely Affect Outcome at 1 Year. The Journal of Infectious Diseases. 174(1). 195–198. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact